COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis
Scientific title
A Phase I Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Study type
Description of intervention(s) / exposure
Other interventions - Placental MSC

Experimental: 1*10^6 MSC / kg - Placental MSC

Experimental: 2*10^6 MSC / kg - Placental MSC

Other interventions: Placental MSC
MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Number of Participants Who Demonstrated Acute Adverse Events Following Infusion - Acute adverse events following infusion was defined as the development of anaphalaxis and/or a 25% increase or decrease from baseline of hemodynamic measurements.
Timepoint [1] 0 0
4 hours post-infusion
Secondary outcome [1] 0 0
Percentage Change in Lung Function as Assessed by FVC Compared to Baseline - Forced Vital Capacity (FVC) was measured and reported as a percentage of predicted and comapred from 6 months post-infusion to baseline
Timepoint [1] 0 0
6 months post MSC infusion
Secondary outcome [2] 0 0
Percentage Change in 6 Minute Walk Distance Compared to Baseline - At 6 months 6 Minute Walk Distance was mesured and compared as a percentage to baseline
Timepoint [2] 0 0
Baseline and 6 months post MSC infusion
Secondary outcome [3] 0 0
Percentage Change in Lung Function as Assessed by DLCO Compared to Baseline - DLCO was measured as a percentage of predicted, and the percentage change between 6 months post-infusion and baseline is reported.
Timepoint [3] 0 0
6 months post MSC infusion

Key inclusion criteria
1. Male or female from 40 to 80 years of age (Note: see exclusion 13 regarding women of
child-bearing potential).

2. Diagnosis of IPF based on the following criteria in accordance with American Thoracic
Society/European Respiratory Society (ATS-ERS) guidelines for diagnosing


Definite or probable usual interstitial pneumonia confirmed on surgical lung biopsy


In absence of SLB, all of the following "major criteria"

- High resolution CT scan (HRCT) showing definite findings for IPF (bibasilar
reticular abnormalities with minimal ground glass opacities)

- Absence of other causes of IPF including drug toxicities, environmental exposure
and connective tissue disease

- Abnormal pulmonary function tests including evidence of a restrictive ventilatory
impairment and impaired gas exchange

- Transbronchial biopsy or BAL suggesting no features of an alternative diagnosis
and three of four of the following "minor criteria"

- Age greater than 50 years

- Insidious onset of otherwise unexplained dyspnea on exertion

- Duration of illness greater than 3 months

- Bibasal, inspiratory crackles

Within 90 days of study enrolment, diagnosis must be confirmed by HRCT chest.

3. Honeycombing greater than 5% in 0 - 3 lung zones (each lung divided into 3 zones - 1)
at the level of the carina 2) highest point of right hemi diaphragm and 3) mid way
between these two levels) as assessed on HRCT.

4. Forced vital capacity (FVC) greater than 50 of predicted with a ratio of forced
expiratory volume in 1 second to FVC (FEV1/FVC) greater than 0.7 (Pulmonary function
tests must be completed no more than 90 days before screening).

5. Diffusing capacity for carbon monoxide (DLCO) greater than 25% of predicted capacity.

6. Ability to perform a 6-Minute Walk Test (6MWT) at screening.

7. Competency to understand the information given in the Human Research and Ethics
Committee (HREC) approved ICF and must sign the form prior to the initiation of any
study procedures.
Minimum age
40 Years
Maximum age
80 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Diagnosis of an interstitial lung disease (ILD) or restrictive lung disease other than

2. Obstructive lung disease as determined by evidence of airflow obstruction on HRCT or
physiologic criteria including:

FEV1/FVC ratio less than 0.7 Residual volume (RV) greater than 120% by plethysmography
or significant (verified by radiologist) emphysema on HRCT if plethysmography not
available Evidence of reactive airway disease by change in FEV1 of greater than 12%
following bronchodilator challenge

3. Evidence of sustained improvement of IPF condition defined as improvement from
pre-therapy pulmonary function tests (PFTs) observed with two or more successive
post-therapy PFTs over the year prior to randomization.

4. Active or recent (less than 60 days prior to enrolment) significant respiratory tract
infection, or a history of frequent (greater than 2 per year for the last 2 years)
infective exacerbations of IPF.

5. Hospitalization within 60 days of screening for an acute exacerbation of IPF (AE-IPF).

6. Chronic heart failure (NYHA class III/IV) or known left ventricular ejection fraction
less than 25%.

7. Chronic treatment with the following drugs prescribed for IPF (within 4 weeks of

oral corticosteroids (greater than 20 mg/day of prednisone or equivalent),
immunosuppressive or cytotoxic drugs, antifibrotic drugs, chronic use of

8. Acute or chronic impairment (other than dyspnea) which limits the ability to comply
with study requirements and procedures including the 6MWD

9. Chronic treatment with immunosuppressive, cytotoxic, or antifibrotic drugs including
pirfenidone, D-penicillamine, colchicine, cyclosporine A, TNF-alpha antagonists,
imatinib, interferon-gamma, cyclophosphamide, or azathioprine within 30 days of

10. Subject requires hemodialysis, peritoneal dialysis or hemofiltration.

11. Systolic blood pressure less than 85 mmHg.

12. History of malignancies within the past 5 years, with the exception of squamous or
basal cell carcinoma of the skin or successfully treated in situ carcinoma of the

13. Female who is of child-bearing potential.

14. Known history of alcohol abuse within 1 year of enrolment.

15. Participation in a clinical study involving another investigational drug or device
within 28 days of screening.

16. Co-morbid condition or illness limiting life expectancy to less than 1 year at time of

17. Serious or active medical or psychiatric illness which, in the opinion of the
Investigator, would interfere with treatment, assessment or compliance with the

18. Significant hypoxemia or hypercapnia at rest on room air as defined by a PaO2 less
than 55mmHg or PaCO2 greater than 50mmHg.

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Prince Charles Hospital - Brisbane
Recruitment postcode(s) [1] 0 0
4032 - Brisbane

Funding & Sponsors
Primary sponsor type
The Prince Charles Hospital
Other collaborator category [1] 0 0
Name [1] 0 0
Mater Medical Research Institute
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Brief summary
The primary objective of this study is to establish the feasibility and safety of infusions
of placental Mesenchymal Stem Cells (MSC) from related or unrelated HLA identical or HLA
mismatched donors in the treatment of Idiopathic Pulmonary Fibrosis (IPF).

The secondary objectives are to document changes in lung function, 6 minute walk distance
(6MWD), gas exchange and radiological appearance following infusion of MSC over a six month
evaluation period.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Daniel Chambers, MBBS MRCP FRACP MD
Address 0 0
The Prince Charles Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications